Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus

Clinical Immunology

Volumn 176, Issue , 2017, Pages 12-22

  Young, Nicholas A ^a   Valiente, Giancarlo R ^a   Hampton, Jeffrey M ^a   Wu, Lai Chu ^a   Burd, Craig J ^a   Willis, William L ^a   Bruss, Michael ^a   Steigelman, Holly ^a   Gotsatsenko, Maya ^a   Amici, Stephanie A ^a   Severin, Mary ^a   Claverie, Lucila Marino ^b   Guerau de Arellano, Mireia ^a   Lovett Racke, Amy ^a   Ardoin, Stacy ^a   Jarjour, Wael N ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Hospital Bernardino Rivadavia   (Argentina)

Author keywords

Estrogen; Extracellular vesicles; Innate immunity; microRNA (miR); Systemic lupus erythematosus; Toll like receptor (TLR)8

Indexed keywords

CHLOROQUINE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 12; INTERLEUKIN 13; MESSENGER RNA; MICRORNA 21; MYELOID DIFFERENTIATION FACTOR 88; STAT1 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; CHEMOKINE; LIGAND; MICRORNA; MIRN21 MICRORNA, HUMAN; STAT1 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

ARTICLE; CELL COMMUNICATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA PROTEIN COMPLEX; DOWN REGULATION; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MACROPHAGE; MCF-7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE-STRANDED RNA VIRUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION INITIATION; UPREGULATION; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHEMOKINES; ESTROGENS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MCF-7 CELLS; MICRORNAS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 8;

EID: 85009250156     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.12.005     Document Type: Article

References (51)

1. [1] Kumar, V., et al. Functional domains of the human estrogen receptor. Cell 51:6 (1987), 941–951.
2. [2] Welboren, W.J., et al. Identifying estrogen receptor target genes. Mol. Oncol. 1:2 (2007), 138–143.
3. [3] Svenson, J.L., et al. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin. Immunol. 128:2 (2008), 259–268.
4. [4] Cunningham, M.A., et al. Estrogen receptor alpha modulates Toll-like receptor signaling in murine lupus. Clin. Immunol. 144:1 (2012), 1–12.
5. [5] Feng, F., et al. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol. 134:2 (2010), 226–236.
6. [6] Young, N.A., et al. Estrogen modulation of endosome-associated toll-like receptor 8: an IFNalpha-independent mechanism of sex-bias in systemic lupus erythematosus. Clin. Immunol. 151:1 (2014), 66–77.
7. [7] Zarember, K.A., Godowski, P.J., Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:2 (2002), 554–561.
8. [8] Aringer, M., Gunther, C., Lee-Kirsch, M.A., Innate immune processes in lupus erythematosus. Clin. Immunol. 147:3 (2013), 216–222.
9. [9] Fabbri, M., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 109:31 (2012), E2110–E2116.
10. [10] Carlsen, A.L., et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 65:5 (2013), 1324–1334.
11. [11] Amarilyo, G., La Cava, A., miRNA in systemic lupus erythematosus. Clin. Immunol. 144:1 (2012), 26–31.
12. [12] Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 40(9), 1997, 1725.
13. [13] Jablonski, K.A., et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS One, 10(12), 2015, e0145342.
14. [14] Young, N.A., et al. Novel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus. Mol. Immunol. 54:1 (2013), 23–31.
15. [15] Burd, C.J., et al., Analysis of chromatin dynamics during glucocorticoid receptor activation. Mol. Cell. Biol. 32(10): p. 1805–17.
16. [16] Heinz, S., et al., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell. 38(4): p. 576–89.
17. [17] Robinson, J.T., et al., Integrative genomics viewer. Nat. Biotechnol. 29(1): p. 24–6.
18. [18] Zannetti, C., et al. C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity. J. Biol. Chem. 285:45 (2010), 34773–34780.
19. [19] Kasperkovitz, P.V., et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann. Rheum. Dis. 63:3 (2004), 233–239.
20. [20] Gysemans, C.A., et al. Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes 54:8 (2005), 2396–2403.
21. [21] Schreiber, S., et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51:3 (2002), 379–385.
22. [22] Dong, J., et al. Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 16:2 (2007), 101–109.
23. [23] Klinge, C.M., Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29:14 (2001), 2905–2919.
24. [24] Bartlett, D.W., Davis, M.E., Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34:1 (2006), 322–333.
25. [25] Chaussabel, D., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:1 (2008), 150–164.
26. [26] Dai, R., et al. Estrogen regulates transcription factors STAT-1 and NF-kappaB to promote inducible nitric oxide synthase and inflammatory responses. J. Immunol. 183:11 (2009), 6998–7005.
27. [27] Akira, S., Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 4:7 (2004), 499–511.
28. [28] Ghosh, T.K., et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell. Immunol. 243:1 (2006), 48–57.
29. [29] Berger, M., et al. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J. Immunother. 32:3 (2009), 262–271.
30. [30] Laxton, C., et al. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob. Agents Chemother. 55:7 (2011), 3105–3114.
31. [31] Kuznik, A., et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186:8 (2011), 4794–4804.
32. [32] Lockshin, M.D., Sex differences in autoimmune disease. Lupus 15:11 (2006), 753–756.
33. [33] Tedeschi, S.K., Bermas, B., Costenbader, K.H., Sexual disparities in the incidence and course of SLE and RA. Clin. Immunol. 149:2 (2013), 211–218.
34. [34] Yoachim, S.D., et al. Estrogen receptor alpha signaling promotes Sle1-induced loss of tolerance and immune cell activation and is responsible for sex bias in B6.Sle1 congenic mice. Clin. Immunol. 158:2 (2015), 153–166.
35. [35] Johnstone, R.M., et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 262:19 (1987), 9412–9420.
36. [36] Valadi, H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:6 (2007), 654–659.
37. [37] Mitchell, P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:30 (2008), 10513–10518.
38. [38] Gallo, A., et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One, 7(3), 2012, e30679.
39. [39] Arroyo, J.D., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108:12 (2011), 5003–5008.
40. [40] Zhang, Y., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 39:1 (2010), 133–144.
41. [41] El-Hefnawy, T., et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 50:3 (2004), 564–573.
42. [42] Guduric-Fuchs, J., et al. Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics, 13, 2012, 357.
43. [43] Nolte-’t Hoen, E.N., et al. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 40:18 (2012), 9272–9285.
44. [44] Bhat-Nakshatri, P., et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 37:14 (2009), 4850–4861.
45. [45] Di Leva, G., et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer Inst. 102:10 (2010), 706–721.
46. [46] Zhao, M., et al. Hypomethylation of IL10 and IL13 promoters in CD4 + T cells of patients with systemic lupus erythematosus. J. Biomed. Biotechnol., 2010, 2010, 931018.
47. [47] Xu, Z., Chen, Y., Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25:3 (2005), 360–361.
48. [48] Hagiwara, E., et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum. 39:3 (1996), 379–385.
49. [49] Garchow, B., Kiriakidou, M., MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus. Clin. Immunol. 162 (2016), 100–106.
50. [50] Rainsford, K.D., et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:5 (2015), 231–269.
51. [51] Hacker, H., et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:21 (1998), 6230–6240.